中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1331 records (took 0.041 seconds)

    METHODS OF CAPTURING CELL-FREE METHYLATED DNA AND USES OF SAME
    193.
    发明申请
    METHODS OF CAPTURING CELL-FREE METHYLATED DNA AND USES OF SAME 审中-公开
    捕获无细胞甲基化DNA的方法及其用途

    公开(公告)号：WO2017190215A1

    公开(公告)日：2017-11-09

    申请号：PCT/CA2017/000108

    申请日：2017-05-03

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： DE CARVALHO, Daniel, Diniz ,  SHEN, Shu, Yi ,  SINGHANIA, Rajat

    IPC: C12Q1/68 ,  C12N15/10 ,  C40B30/04

    Abstract: There is described herein, a method of capturing cell-free methylated DNA from a sample having less than 100 mg of cell-free DNA, comprising the steps of: subjecting the sample to library preparation to permit subsequent sequencing of the cell-free methylated DNA; adding a first amount of filler DNA to the sample, wherein at least a portion of the filler DNA is methylated; denaturing the sample; and capturing cell-free methylated DNA using a binder selective for methylated polynucleotides.

    Abstract translation: 本文描述了从具有少于100mg无细胞DNA的样品中捕获无细胞甲基化DNA的方法，其包括步骤：使样品经过文库制备以允许随后 无细胞甲基化DNA的测序; 向样品中加入第一量的填料DNA，其中至少一部分填料DNA被甲基化; 使样品变性; 并使用对甲基化多核苷酸具有选择性的结合剂来捕获无细胞甲基化DNA。

    PEPT1DE-HLA COMPLEXES AND METHODS OF PRODUCING SAME
    194.
    发明申请
    PEPT1DE-HLA COMPLEXES AND METHODS OF PRODUCING SAME 审中-公开
    PEPT1DE-HLA复合物及其生产方法

    公开(公告)号：WO2017185169A1

    公开(公告)日：2017-11-02

    申请号：PCT/CA2017/000102

    申请日：2017-04-27

    Applicant: UNIVERSITY HEALTH NETWORK (UHN)

    Inventor： HIRANO, Naoto ,  NAKATSUGAWA, Munehide ,  RAHMAN, Muhammed Aashiq

    IPC: C07K14/74 ,  C12N15/12 ,  C12N5/10 ,  G01N33/53 ,  G01N33/569

    Abstract: There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class 1 molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises a1, a1, a2, a3 and β2m domains.

    Abstract translation: 本文提供了哺乳动物来源的HLA I类分子用于体外肽交换的用途。 例如，提供了产生与预先选择的肽复合的HLA I类分子的方法，其包括：（a）提供与现有肽复合的哺乳动物来源的HLA 1类分子; （b）在体外将与现有肽复合的HLA I类分子与预先选择的肽一起温育，其中预选肽的浓度足以替代现有的肽以产生与HLA复合的HLA I类分子 预先选择的肽; 并且HLA I类分子包含α1，α1，α2，α3和β2m结构域。

    BIODEGRADABLE SOFT TISSUE FILLER
    195.
    发明申请
    BIODEGRADABLE SOFT TISSUE FILLER 审中-公开
    可生物降解的软组织填充物

    公开(公告)号：WO2017139868A1

    公开(公告)日：2017-08-24

    申请号：PCT/CA2017/000030

    申请日：2017-02-16

    Applicant: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO ,  UNIVERSITY HEALTH NETWORK

    Inventor： SANTERRE, Paul ,  SHARIFPOOR, Soror ,  LEONG, Liang, Wey

    IPC: A61L27/18 ,  A61L27/56

    CPC classification number: A61L27/18 ,  A61L27/56 ,  A61L27/58 ,  A61L2400/06 ,  A61L2430/04 ,  C08L75/04

    Abstract: A soft tissue filler comprising a biodegradable amino-acid derived polycarbonate-urethanes and methods of repairing soft tissue defects are provided. The biodegradable soft tissue filler comprises a porous scaffold that is the reaction product of: a) a divinyl oligomer component that comprises a carbonate-derived divinyl oligomer that is the reaction product of a lysine-derived diisocyanate, a vinyl coupling agent, and a polycarbonate and, optionally, an ether-derived divinyl oligomer, wherein the ether-derived divinyl oligomer is the reaction product of a lysine-derived diisocyanate, a vinyl coupling agent, and an ether; b) at least one anionic monomer; and c) at least one hydrophobic monomer. The molar ratio of (a) : (b+c) is between about 1:≥21 and about 1:30, the soft tissue filler has a porosity of > 75 %; and a compressive moduli of between about 1 kPa and about 50 kPa.

    Abstract translation: 提供了包含可生物降解的氨基酸衍生的聚碳酸酯 - 氨基甲酸酯的软组织填充物以及修复软组织缺陷的方法。 可生物降解的软组织填充物包括多孔支架，所述多孔支架是以下物质的反应产物：a）二乙烯基低聚物组分，其包含碳酸酯衍生的二乙烯基低聚物，其为赖氨酸衍生的二异氰酸酯，乙烯基偶联剂和聚碳酸酯 以及任选地衍生自醚的二乙烯基低聚物，其中所述衍生自醚的二乙烯基低聚物是赖氨酸衍生的二异氰酸酯，乙烯基偶联剂和醚的反应产物; b）至少一种阴离子单体; 和c）至少一种疏水单体。 （a）：（b + c）的摩尔比在约1:21和约1:30之间，软组织填充剂的孔隙率> 75％; 和在约1kPa和约50kPa之间的压缩模量。

    CANCER TREATMENT USING NK CELLS
    196.
    发明申请
    CANCER TREATMENT USING NK CELLS 审中-公开
    使用NK细胞的癌症治疗

    公开(公告)号：WO2017137595A3

    公开(公告)日：2017-08-17

    申请号：PCT/EP2017/053061

    申请日：2017-02-10

    Applicant: ONKOCELLULAR LIMITED ,  UNIVERSITY HEALTH NETWORK

    Inventor： KEATING, Armand ,  WILLIAMS, Brent, Allen ,  WANG, Xing-Hua ,  O'DWYER, Michael, Eamon, Peter ,  SCHLICH, George, William

    IPC: C07K16/28 ,  A61K39/395 ,  A61K35/17 ,  A61P35/02 ,  A61K39/00

    Abstract: Treatment of cancer in a patient comprises administering to the patient an antibody and a non-antibody agent that activates the patient's own NK cells, wherein the antibody binds an antigen on the surface of the patient's own NK cells and the antibody Fc region binds to an Fc receptor on a cell of the cancer. Anticancer activity is via resultant killing action of the NK cell on the cancer cell, now binding the antibody Fc region, via reverse antibody-dependent cell-mediated cytotoxicity (R-ADCC).

    Abstract translation: 治疗患者中的癌症包括向患者施用激活患者自身NK细胞的抗体和非抗体剂，其中所述抗体结合患者自身NK细胞表面上的抗原 并且抗体Fc区与癌细胞上的Fc受体结合。 抗癌活性是通过经由反向抗体依赖性细胞介导的细胞毒性（R-ADCC）现在结合抗体Fc区的NK细胞对癌细胞的杀伤作用产生的。

    MULTI-MODAL PROSTATE CANCER MARKER
    198.
    发明申请
    MULTI-MODAL PROSTATE CANCER MARKER 审中-公开
    多模式前列腺癌标记物

    公开(公告)号：WO2017132748A1

    公开(公告)日：2017-08-10

    申请号：PCT/CA2017/000023

    申请日：2017-02-02

    Applicant: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) ,  UNIVERSITY HEALTH NETWORK

    Inventor： BOUTROS, Paul ,  BRISTOW, Robert, G., Dr. ,  SHIAH, Sylvia ,  FRASER, Michael, Dr. ,  SABELNYKOVA, Veronica ,  HUANG, Vincent ,  HEISLER, Lawrence, Dr. ,  YAMAGUCHI, Takafumi ,  LIVINGSTONE, Julie

    IPC: C12Q1/68 ,  G01N33/48 ,  G06F19/10 ,  G06F19/20

    CPC classification number: G06F19/20 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/156 ,  G06F19/18

    Abstract: There is described herein a method of prognosing and/or predicting disease progression in subject with prostate cancer, the method comprising: a) providing a sample containing genetic material from cancer cells; b)determining or measuring at least 2 patient biomarkers regarding the prostate cancer tumor selected from the group consisting of: T category, ACTL6B methylation, TCERGL1 methylation, chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations; c) comparing said patient biomarkers to corresponding reference or control biomarkers; and d) determining the likelihood of disease progression; wherein a likelihood of disease progression is higher with each of ACTL6B hyper-methylation, TCERGL1 hypo-methylation, higher T category, and higher incidences of chr7:61 Mbp inter-chromosomal translocation, ATM single nucleotide variants and MYC copy number aberrations, when the difference is statistically significant on comparison with the reference or control biomarkers.

    Abstract translation: 本文描述了预后和/或预测前列腺癌患者的疾病进展的方法，所述方法包括：a）提供含有来自癌细胞的遗传物质的样品; b）确定或测量选自T类，ACTL6B甲基化，TCERGL1甲基化，chr7：61Mbp染色体间易位，ATM单核苷酸变体和MYC拷贝数畸变的至少2种患者生物标志物; c）将所述患者生物标志物与相应的参考或对照生物标志物进行比较; 和d）确定疾病进展的可能性; 其中当ACTL6B高甲基化，TCERGL1低甲基化，高T类和CHr7：61Mbp染色体间易位，ATM单核苷酸变体和MYC拷贝数畸变的发生率更高时，疾病进展的可能性更高 与参照或对照生物标志物相比，差异具有统计学显着性。

    SENSORS WITH VIRTUAL SPATIAL SENSITIVITY FOR MONITORING A RADIATION GENERATING DEVICE
    199.
    发明申请
    SENSORS WITH VIRTUAL SPATIAL SENSITIVITY FOR MONITORING A RADIATION GENERATING DEVICE 审中-公开
    具有虚拟空间灵敏度的传感器，用于监测辐射发生装置

    公开(公告)号：WO2016191883A1

    公开(公告)日：2016-12-08

    申请号：PCT/CA2016/050635

    申请日：2016-06-03

    Applicant: UNIVERSITY HEALTH NETWORK

    Inventor： ISLAM, Mohammad Khairul ,  HEATON, Robert K. ,  JAFFRAY, David A. ,  NORRLINGER, Bernhard Dieter

    IPC: G01T1/185 ,  H01J47/02 ,  H01J47/08

    CPC classification number: G01T1/185 ,  H01J47/02

    Abstract: Various embodiments are described herein for sensors that may be used to measure radiation from radiation generating device. The sensors may use a collector plate electrode with first and second collection regions having shapes that are inversely related with one another to provide ion chambers with varying sample volumes along a substantial portion of the first and second collection regions which provides virtual spatial sensitivity during use.

    Abstract translation: 本文描述了可用于测量来自辐射发生装置的辐射的传感器的各种实施例。 传感器可以使用具有第一和第二收集区域的收集板电极，该第一和第二收集区域具有彼此负相关的形状，以提供具有沿第一和第二收集区域的实质部分变化的样品体积的离子室，其在使用期间提供虚拟空间灵敏度。

Patent Agency Ranking